Pivotal bioVenture Partners Investment Advisor LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001844645

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 13 positions · Total reported value $245.36M · Top-10 concentration 93.5% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.7% · 1 new · 3 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.9% · vs SPY -16.0% · Prev Value $307.79M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.7% · vs SPY -2.9% · Latest Value $245.36M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Pivotal bioVenture Partners Investment Advisor LLC disclosed 13 equity positions with a combined reported value of $245.36M. The filing implies a focused portfolio: its ten largest positions account for 93.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PCVX ($81.11M), ARQT ($26.65M), TRVI ($24.96M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Pivotal bioVenture Partners Investment Advisor LLC opened 1 new positions, trimmed 3 and fully exited 1, a turnover rate of 35.7% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q3 2026 were VRDN ($11.81M).

Of the 1 positions fully exited versus the prior quarter, the largest were RXRX ($2.19M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VRDN VIRIDIAN THERAPEUTICS INC · $11.81M

Fully Exited (vs previous quarter)

  • RXRX RECURSION PHARMACEUTICALS IN · prev qtr: $2.19M

Insider Transactions (Form 4)

Latest Pivotal bioVenture Partners Investment Advisor LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Pivotal bioVenture Partners Investment Advisor LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 13 US equity positions with a combined value of $307.79M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 13 positions · $307.79M reported value (Q2 2026)
  • Top 10 holdings = 95.1% of reported value
  • Largest position: PCVX (VAXCYTE INC) at 26.9%
  • Average position size: $23.68M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 added, 3 reduced, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to PCVX and IMNM (weight rises due to price, not share changes), while reducing positions in ARQT, AVLN, and ZBIO, suggesting a cautious stance on some biotech holdings but confidence in select names like VAXCYTE. The addition of VRDN indicates opportunistic bets on new pipelines. 2. Key moves: - Added: VRDN (new position, 4.81% weight). - Reduced: ARQT (-20.3% shares), AVLN (-10.3% shares), ZBIO (-52.5% shares). - Increased weight (price-driven): PCVX (+6.14% wt), IMNM (+1.38% wt). 3. Portfolio structure: Active, concentrated (13 positions), heavily biased toward Health Care (100%), with high conviction in top holdings (PCVX alone 33.06%). Risk appetite is moderate, with frequent rebalancing (3 reductions, 1 add, 1 new). 4. Per-holding one-liner: - PCVX: VAXCYTE INC (unverified, likely vaccines/immunotherapy). - ARQT: ARCUTIS BIOTHERAPEUTICS INC (unverified, dermatology/biotherapeutics). - TRVI: TREVI THERAPEUTICS INC (unverified, kidney/urology drugs). - AVLN: AVALYN PHARMACEUTICALS INC (unverified, respiratory/pulmonary). - EVMN: EVOMMUNE INC (unverified, autoimmune therapies). - IMNM: IMMUNOME INC (unverified, oncology/diagnostics). - OCS: OCULIS HOLDING AG (unverified, eye disease treatments). - VRDN: VIRIDIAN THERAPEUTICS INC (unverified, thyroid disorders). - AVTX: AVALO THERAPEUTICS INC (unverified, lung cancer therapies). - ZBIO: ZENAS BIOPHARMA INC (unverified, oncology/immunology). 5. Style summary: A concentrated, actively managed Health Care fund that selectively trims underperforming biotech names while doubling down on high-conviction winners and adding new pipeline candidates.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 02:44

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.43M $81.11M 33.06%
33.06%
Hold
2 1.01M $26.65M 10.86%
10.86%
Reduce
3 1.74M $24.96M 10.17%
10.17%
Hold
4 866.79K $24.69M 10.06%
10.06%
Reduce
5 1.93M $15.92M 6.49%
6.49%
Hold
6 732.51K $15.76M 6.42%
6.42%
Hold
7 1.66M $15.49M 6.32%
6.32%
Add
8 860.34K $11.81M 4.81%
4.81%
New
9 434.03K $6.65M 2.71%
2.71%
Hold
10 233.18K $6.29M 2.56%
2.56%
Reduce
11 611.45K $6.23M 2.54%
2.54%
Hold
12 300.58K $5.17M 2.11%
2.11%
Hold
13 653.37K $4.63M 1.89%
1.89%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Historical Backtest (11 quarters)

Avg precision 84% · recall 84% · F1 84% · avg rank error 1.6 · Top-10 turnover 15%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% KRTX · PCVX · OCS · INZY · FUSN · GRCL · ARQT · RLYB · EXAI · BOLT PCVX · INZY · ARQT · OCS · FUSN · RLYB · EXAI · BOLT · VIGL · IOBTQ
2024-Q2 90% 90% 90% PCVX · INZY · ARQT · OCS · FUSN · RLYB · EXAI · BOLT · VIGL · IOBTQ PCVX · INZY · OCS · ARQT · EXAI · RLYB · VIGL · BOLT · IOBTQ · ALGS
2024-Q3 80% 80% 80% PCVX · INZY · ARQT · OCS · EXAI · RLYB · VIGL · BOLT · IOBTQ · ALGS PCVX · INZY · ARQT · OCS · ZBIO · BIOA · EXAI · RLYB · VIGL · BOLT
2024-Q4 90% 90% 90% PCVX · INZY · ARQT · OCS · ZBIO · BIOA · EXAI · RLYB · VIGL · BOLT PCVX · OCS · ARQT · INZY · ZBIO · RXRX · BIOA · RLYB · BOLT · VIGL
2025-Q1 90% 90% 90% PCVX · OCS · ARQT · INZY · ZBIO · RXRX · BIOA · RLYB · BOLT · VIGL OCS · ARQT · PCVX · ZBIO · INZY · RXRX · BIOA · RLYB · VIGL · IOBTQ
2025-Q2 90% 90% 90% OCS · ARQT · PCVX · ZBIO · INZY · RXRX · BIOA · RLYB · VIGL · IOBTQ OCS · PCVX · ARQT · INZY · ZBIO · TRVI · VIGL · RXRX · BIOA · IOBTQ
2025-Q3 70% 70% 70% PCVX · OCS · ARQT · INZY · ZBIO · TRVI · VIGL · RXRX · BIOA · IOBTQ PCVX · OCS · ARQT · ZBIO · TRVI · IMNM · BIOA · RXRX · RLYB · BOLT
2025-Q4 80% 80% 80% PCVX · OCS · ARQT · ZBIO · TRVI · IMNM · BIOA · RXRX · RLYB · BOLT PCVX · OCS · ARQT · EVMN · ZBIO · TRVI · IMNM · MPLT · BIOA · RXRX
2026-Q1 90% 90% 90% PCVX · OCS · ARQT · EVMN · ZBIO · IMNM · TRVI · MPLT · BIOA · RXRX PCVX · OCS · EVMN · ARQT · TRVI · IMNM · MPLT · ZBIO · BIOA · AVTX
2026-Q2 90% 90% 90% PCVX · EVMN · OCS · ARQT · TRVI · IMNM · MPLT · BIOA · ZBIO · AVTX PCVX · ARQT · TRVI · AVLN · EVMN · MPLT · OCS · BIOA · IMNM · ZBIO
2026-Q3 ★ 80% 80% 80% PCVX · TRVI · ARQT · AVLN · EVMN · MPLT · OCS · BIOA · IMNM · ZBIO PCVX · ARQT · TRVI · AVLN · EVMN · IMNM · OCS · VRDN · AVTX · ZBIO

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Pivotal bioVenture Partners Investment Advisor LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Pivotal bioVenture Partners Investment Advisor LLC reported 13 equity positions worth $245.36M in aggregate; its largest disclosed positions were PCVX ($81.11M), ARQT ($26.65M), TRVI ($24.96M).

How large is Pivotal bioVenture Partners Investment Advisor LLC's portfolio?

Pivotal bioVenture Partners Investment Advisor LLC reported $245.36M of long equity holdings across 13 positions as of 2026-Q3. Top-10 holdings account for 93.5% of reported value.

What is Pivotal bioVenture Partners Investment Advisor LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pivotal-bioventure-partners-investment-advisor/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →